Abstract:Abstract Background Chemotherapy remains the mainstay of treatment for various cancers. However recent studies suggested that it may also induce local or systemic changes that promote the dissemination and proliferation of cancer cells leading to successful metastasis. Understanding this process is therefore instrumental to help us identify patient population that may or may not be benefit from chemotherapy, and develop innovative approaches to prevent metastasis. Methods In this study, we investigated the mechanism of chemotherapy causing the metastasis of colorectal cancer, and the roles of G-CSF induced by chemotherapy in the vessel formation. Eight-week-old C57/BL6 mice were used as animal models in this study to investigate the lung metastasis by the chemotherapy. Conditional endothelial cell STAT3−/− (Signal Transducer and Activator of Transcription, STAT) knockout mice (STAT3flox/flox; Tek-Cre mice), were used to investigate the function of STAT3 on lung metastasis under the chemotherapy. Bone marrow and plasma was selected to detect the mobilization of endothelial progenitor cells (EPCs) and MDSCs. To trace BM-derived cells, we prepared chimeric mouse transplanted with BM cells from green fluorescent protein (GFP) transgenic mouse. In vitro, experiments were performed in human umbilical vein endothelial cells (HUVEC) to analyse the function of G-CSF on angiogenesis. Detected the G-CSF content in the plasma of the patients who received an adjuvant chemotherapy with the XELOX (oxaliplatin plus capecitabine) regimen. Results Our study showed that oxaliplatin chemotherapy could increase the expression of G-CSF to promote lung metastasis. First, G-CSF/STAT3 signaling facilitated lung metastasis by enhancing vascular adhesion rather than diminishing the blood vessel density. G-CSF also promoted Endothelial Progenitor Cells (EPCs) mobilization that devoted to vasculogenesis, a critical step for vessel density in metastatic sites; moreover, chemotherapy augmented the mobilization of MDSCs from the bone marrow by G-CSF. In consistent with these, anti-G-CSF suppressed the formation of a functional vasculature and induced tumoral immunosuppression, resulting in an anti-metastasis effect during chemotherapy. Furthermore, at human level, we observed high level of G-CSF, either at baseline or after receiving adjuvant XELOX chemotherapy, correlated with poor overall and recurrence-free survival. Conclusions These results demonstrate that certain chemotherapy could paradoxically result in worse outcome due to increased expression of G-CSF. Our findings provide mechanistic insight into cautious use of G-CSF and potential utility of anti-G-CSF in personalized cancer therapy.

Recombinant Human Granulocyte Colony-Stimulating Factor is Associated with Increased Risk of Metastasis in NSCLC Patients Following Postoperative Chemotherapy: A Retrospective Cohort Study

rhG-CSF is associated with an increased risk of metastasis in NSCLC patients following postoperative chemotherapy

The Impact of Rhg-Csf on Risk of Recurrence after Postoperative Chemotherapy in NSCLC Patients: A Retrospective Cohort Study

Association of Granulocyte Colony-Stimulating Factor Treatment with Risk of Brain Metastasis in Advanced Stage Breast Cancer

Associations of Granulocyte Colony-Stimulating Factor with Toxicities and Efficacy of Chimeric Antigen Receptor T-cell Therapy in Relapsed or Refractory Multiple Myeloma

Role of recombinant human granulocyte colony-stimulating factor in development of cancer-associated venous thromboembolism in lung cancer patients who undergo chemotherapy

Treatment with Granulocyte-colony Stimulating Factor (G-CSF) is not associated with Increased Risk of Brain Metastasis in Patients with De Novo Stage IV Breast Cancer

Granulocyte colony-stimulating factor has the potential to attenuate the therapeutic efficacy of chemo-immunotherapy for extensive-stage small-cell lung cancer

Chemotherapy May Facilitate Colorectal Cancer Metastasis Through Vessel Formation by Upregulating G-CSF

A clinical study of polyethylene glycol recombinant human granulocyte colony-stimulating factor prevention neutropenia syndrome in patients with esophageal carcinoma and lung cancer after concurrent chemoradiotherapy

Safety and efficacy of pegylated recombinant human granulocyte colony-stimulating factor during concurrent chemoradiotherapy for small-cell lung cancer: a retrospective, cohort-controlled trial

Clinical Significance of Serum Granulocyte Colony-stimulating Factor Level in Patients with Non-small-cell Lung Carcinoma

Granulocyte growth factors in the treatment of non-small cell lung cancer (NSCLC)

Granulocyte Colony-Stimulating Factor Treatment During Radiotherapy Is Associated With Survival Benefit in Patients With Lung Cancer.

Efficacy and safety of 3 mg pegylated recombinant human granulocyte colony-stimulating factor as support to chemotherapy for lung cancer

Risk of Neutropenia-Related Hospitalization in Patients Who Received Colony-Stimulating Factors With Chemotherapy for Breast Cancer

Association Between Granulocyte Colony-Stimulating Factor (G-CSF) Use and Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Among Elderly Patients with Breast, Lung, or Prostate Cancer

PEG-rhG-CSF for prophylaxis of neutropenia after chemotherapy in patients with non-small cell lung cancer: A multicenter, prospective, randomized study

Application of Pegylated Recombinant Human Granulocyte Colony-Stimulating Factor to Prevent Chemotherapy-Induced Neutropenia in Patients with Lymphoma:A Prospective,multicenter,open-Label Clinical Trial

The Effect of Neutropenia and Filgrastim (G-CSF) on Cancer Patients With Coronavirus Disease 2019 (COVID-19) Infection

Pegylated Recombinant Human Granulocyte Colony‐stimulating Factor Regulates the Immune Status of Patients with Small Cell Lung Cancer